Literature DB >> 28637590

Evaluation of readmissions due to surgical site infections: A potential target for quality improvement.

Romil Shah1, Emily Pavey1, Mila Ju2, Ryan Merkow2, Ravi Rajaram2, Michael W Wandling2, Mark E Cohen3, Allison Dahlke1, Anthony Yang1, Karl Bilimoria4.   

Abstract

INTRODUCTION: Readmissions have become a focus of pay-for-performance programs. Surgical site infections (SSI) are the reason for most readmissions. Readmissions for SSI could be a unique target for quality improvement.
METHODS: Readmission risk for SSI were evaluated for patients undergoing colectomies from 2013 to 2014. Hazard models were developed to examine factors associated with and hospital-level variation in risk-adjusted rates of readmission for SSI.
RESULTS: Among 59,088 patients at 525 hospitals, the rate of readmissions for SSI ranged from 1.45% to 6.34%. Characteristics associated with a greater likelihood of SSI readmissions include male gender, smoking, open surgery and hospitals with increased socioeconomically-disadvantaged patients. After risk adjustment, there was little correlation between hospital performance with SSI readmission rate and performance with overall SSI or total readmission rate (r2 = 0.29, r2 = 0.14).
CONCLUSIONS: Readmission for SSI represents a unique aspect of quality beyond that offered by measuring only SSI or readmission rates alone, and may provide actionable quality improvement.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28637590     DOI: 10.1016/j.amjsurg.2017.04.011

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  2 in total

1.  Hospital admissions due to infectious and parasitic diseases in England and Wales between 1999 and 2019: an ecological study.

Authors:  Kanar Sweiss; Abdallah Y Naser; Mohammed Samannodi; Hassan Alwafi
Journal:  BMC Infect Dis       Date:  2022-04-23       Impact factor: 3.667

2.  A Biofabrication Strategy for a Custom-Shaped, Non-Synthetic Bone Graft Precursor with a Prevascularized Tissue Shell.

Authors:  Sarah M Moss; Monica Ortiz-Hernandez; Dmitry Levin; Chris A Richburg; Thomas Gerton; Madison Cook; Jeffrey J Houlton; Zain H Rizvi; Paul C Goodwin; Michael Golway; Beth Ripley; James B Hoying
Journal:  Front Bioeng Biotechnol       Date:  2022-03-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.